一品红(300723) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was ¥514,757,244.68, representing a 51.70% increase compared to ¥339,319,563.39 in the same period last year[9] - Net profit attributable to shareholders was ¥68,040,684.42, up 57.31% from ¥43,252,000.55 year-on-year[9] - Basic earnings per share rose to ¥0.42, reflecting a 55.56% increase from ¥0.27 in the same quarter last year[9] - The company achieved operating revenue of 514.76 million yuan, a year-on-year increase of 51.70%[30] - Net profit attributable to shareholders reached 68.04 million yuan, up 57.31% year-on-year, while the net profit after deducting non-recurring items was 64.58 million yuan, a 40.17% increase[30] - The total comprehensive income for the current period is 67,695,010.56, compared to 43,196,331.66 in the previous period, reflecting an increase of approximately 56.7%[85] Cash Flow - The net cash flow from operating activities improved significantly to ¥11,466,282.29, a 120.93% increase from a negative cash flow of ¥54,795,771.22 in the previous year[9] - Cash received from operating activities rose by 45.19% due to increased sales revenue[26] - The cash inflow from operating activities totaled CNY 569,479,774.31, compared to CNY 381,249,816.47 in the previous period, representing an increase of approximately 49.4%[97] - The net cash flow from operating activities was CNY 11,466,282.29, a significant recovery from a net outflow of CNY 54,795,771.22 in the previous period[97] - Cash inflow from financing activities reached CNY 772,394,716.97, compared to CNY 364,000,000.00 in the previous period, marking an increase of approximately 112.4%[99] - The net cash flow from financing activities was CNY 469,706,220.31, up from CNY 192,622,178.63 in the previous period, reflecting a growth of about 143.5%[99] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,600,429,272.32, a 21.22% increase from ¥2,145,157,902.64 at the end of the previous year[9] - The total liabilities increased to ¥688,729,076.35 from ¥580,559,559.70, reflecting a growth in financial obligations[73] - The total equity attributable to shareholders rose to ¥973,768,027.60 from ¥889,856,423.93, showing a positive trend in shareholder value[73] - The company's total current assets increased to RMB 1,603,917,560.84 from RMB 1,209,029,589.83 as of December 31, 2020, reflecting a growth of approximately 32.6%[57] - The company's cash and cash equivalents rose to RMB 898,619,042.35 as of March 31, 2021, compared to RMB 726,032,154.71 at the end of 2020, marking an increase of about 23.7%[57] Expenses - Research and development expenses rose by 65.33% as projects resumed normal operations after pandemic delays[26] - Sales expenses increased by 60.47%, reflecting higher sales performance and bonuses for sales personnel[26] - The total operating costs for the current period are 445,249,979.39, compared to 283,992,660.75 in the previous period, which is an increase of approximately 57%[81] - The management expenses for the current period are 33,705,534.61, compared to 15,637,421.61 in the previous period, which is an increase of approximately 115%[81] - The financial expenses for the current period are 4,042,906.49, down from 9,101,034.88, showing a decrease of about 55.6%[81] Shareholder Information - The total number of shareholders at the end of the reporting period was 8,884, with the largest shareholder holding 42.26% of the shares[13] - The company implemented a second phase of the employee stock incentive plan, targeting a revenue growth rate for self-developed products of no less than 25%, 56%, 95%, and 144% from 2021 to 2024[31] Government Support and Subsidies - The company received government subsidies amounting to ¥3,400,394.95 during the reporting period, primarily recognized as current income[9] - Operating income increased by 3,796.26% due to government rewards received during the reporting period[26] Product Development and Portfolio - The company received several drug registration certificates, including for Ambroxol Hydrochloride Injection and Acyclovir Injection, enhancing its product portfolio[33] - The leading product, Clindamycin Palmitate Ester Dispersible Tablets, saw revenue growth of 64.04% year-on-year[30] Fundraising and Investments - The company is progressing with its fundraising projects, with a total of 101.31 million yuan raised, of which 46.81 million yuan has been invested[39] - The company successfully issued convertible bonds, which are now listed on the Shenzhen Stock Exchange[31] - The company issued convertible bonds, resulting in a significant increase in payable bonds[26]